Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Ma-Weaver JacobOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Hove Anders DOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Mitchell Daniel JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Flynn James POwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Conway Robert EOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Grais LindaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Woosley Raymond L.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
Filings by filing date
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Ma-Weaver JacobOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Hove Anders DOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Mitchell Daniel JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Flynn James POwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Conway Robert EOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Grais LindaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
-
Jan 30, 2024 (filed on Jan 31, 2024)Insider Name:Woosley Raymond L.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10170 Church Ranch Way, Suite 100 WESTMINSTER CO 80021 |
Tel: | N/A |
Website: | https://arcabio.com |
IR: | See website |
Key People | ||
Thomas A. Keuer President, Principal Executive Officer, Chief Operating Officer | C. Jeffrey Jeffrey Dekker Chief Financial Officer |
Business Overview |
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options. |
Financial Overview |
For the fiscal year ended 31 December 2023, Arca Biopharma Inc revenues was not reported. Net loss decreased 46% to $5.3M. Lower net loss reflects Other -Research and development decrease of 82% to $853K (expense), Interest and other income increase from $675K to $2M (income), Rental Expense decrease of 5% to $119K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.69 to -$0.37. |
Employees: | 4 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $15.21M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$7.28M as of Dec 31, 2023 |
Net annual income (TTM): | -$5.34M as of Dec 31, 2023 |
Free cash flow (TTM): | -$5.01M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 14,501,143 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |